Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALOMA-3
jRCT2041220053Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of lazertinib, amivantamab and hyaluronidase in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Observed serum concentration (Ctrough) of amivantamab at steady state on Cycle 4 Day 1, Observed serum concentration (Ctrough) of amivantamab at pre-dose on Cycle 2 Day 1 and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
lazertinibamivantamabhyaluronidase
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2041220053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220053.